Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non–small cell lung cancer. Issue 4 (18th January 2013)

• Record Type: Journal Article
• Authors: Harada, Hiroaki; Miyamoto, Kazuaki; Yamashita, Yoshinori; Nakano, Kikuo; Taniyama, Kiyomi; Miyata, Yoshihiro; Ohdan, Hideki; Okada, Morihito
• Is Part Of: Cancer. Volume 119:Issue 4(2013)
• Page Start: 792
• Page End: 798
• Publication Date: 2013-01-18
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.27754
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>BACKGROUND:</title> <p>Even after early detection and curative resection of early stage non–small cell lung cancer (NSCLC), a significant fraction of patients develop recurrent disease. Molecular biomarkers that can predict the risk of recurrence thus need to be identified to improve clinical outcomes.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>METHODS:</title> <p>Using the methylation‐specific polymerase chain reaction assay, promoter methylation of the breast cancer susceptibility gene 1 (<italic>BRCA1</italic>) was assessed in cancer tissues from 70 patients with curatively resected stage I NSCLC. The clinical relevance of <italic>BRCA1</italic> methylation status was evaluated in terms of outcome of the disease.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>RESULTS:</title> <p>Methylation of the <italic>BRCA1</italic> promoter was detected in 13 of 70 patients (18.6%). Multiple logistic regression analysis revealed that <italic>BRCA1</italic> methylation was an independent risk factor for recurrence (<italic>P</italic> = .0197) and that patients with <italic>BRCA1</italic> methylation demonstrated significantly poorer recurrence‐free survival compared to those without (<italic>P</italic> = .0139). Cox's proportional hazard regression analysis revealed that <italic>BRCA1</italic> methylation was an independent risk factor for recurrence‐free survival (<italic>P</italic> = .0155).</p> </sec> <sec id="abs1-4" sec-type="section"> <title>CONCLUSIONS:</title> <p>Methylated <italic>BRCA1</italic> can be a potential biomarker that predicts the prognosis after curative resection of stage I NSCLC. Considering that <italic>BRCA1</italic> plays a role in chemotherapy‐induced apoptosis, it is plausible that identification of methylated <italic>BRCA1</italic> could provide information that is clinically relevant to tailored adjuvant therapy. Cancer 2013. © 2013 American Cancer Society.</p> </sec> </abstract>